Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Mar 20;40(9):924-926.
doi: 10.1200/JCO.21.02667. Epub 2022 Jan 19.

Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion

Dario R Roque  1   2 , Daniela Matei  1   2
Affiliations
Editorial

Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion

Dario R Roque et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dario R. RoqueHonoraria: Intuitive SurgicalConsulting or Advisory Role: Myriad GeneticsSpeakers' Bureau: GlaxoSmithKlineTravel, Accommodations, Expenses: Intuitive Surgical Daniela MateiHonoraria: Tesaro, Radius Health, GlaxoSmithKline, Clovis Oncology, Merck, AstraZenecaConsulting or Advisory Role: AstraZeneca, Clovis Oncology, Astex Pharmaceuticals, Roche/Genentech, Merck, GlaxoSmithKlineResearch Funding: Merck, MerckTravel, Accommodations, Expenses: AstraZeneca, Genentech/Roche, Radius HealthNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Model illustrates putative origin of carcinosarcoma in an epithelial progenitor with late dedifferentiation to sarcoma. Common mutations and drivers of EMT are shown. Illustration was created in BioRender. CP, carboplatin/paclitaxel; EMT, epithelial to mesenchymal transition; TGF, transforming growth factor.
See this image and copyright information in PMC

Comment on

References

    1. Matsuo K, Ross MS, Machida H, et al. Trends of uterine carcinosarcoma in the United States. J Gynecol Oncol. 2018;29:e22. - PMC - PubMed
    1. Cantrell LA, Blank SV, Duska LR.Uterine carcinosarcoma: A review of the literature Gynecol Oncol 137581–5882015 - PubMed
    1. Gotoh O, Sugiyama Y, Takazawa Y, et al. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat Commun. 2019;10:4965. - PMC - PubMed
    1. Cherniack AD, Shen H, Walter V, et al. Integrated molecular characterization of uterine carcinosarcoma Cancer Cell 31411–4232017 - PMC - PubMed
    1. Powell MA, Filiaci VL, Hensley ML, et al. Randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and ifosfamide in patients with carcinosarcoma of the uterus or ovary: An NRG oncology trial J Clin Oncol 40968–9772022 - PMC - PubMed

MeSH terms